Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2024-2032

Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2024-2032


The global immunomodulators market size reached US$ 211.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 331.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.

Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).

Immunomodulators Market Trends:

The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global immunomodulators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.

Breakup by Product:
  • mmunosuppressants
  • Antibodies
  • Calcineurin Inhibitors
  • Glucocorticoids
  • Antimetabolites
  • Others
  • mmunostimulants
  • Vaccines
  • Antibodies
  • Others
Breakup by Application:
  • Oncology
  • Respiratory
  • HIV
  • Others
Breakup by Region:
  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:
  • How has the global immunomodulators market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global immunomodulators market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global immunomodulators market and who are the key players?
  • What is the degree of competition in the industry?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Immunomodulators Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Immunosuppressants
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Antibodies
6.1.2.2 Calcineurin Inhibitors
6.1.2.3 Glucocorticoids
6.1.2.4 Antimetabolites
6.1.2.5 Others
6.1.3 Market Forecast
6.2 Immunostimulants
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Vaccines
6.2.2.2 Antibodies
6.2.2.3 Others
6.2.3 Market Forecast
7 Market Breakup by Application
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Respiratory
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 HIV
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Biogen Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Bristol-Myers Squibb Company
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Eli Lilly and Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 F. Hoffmann-La Roche AG
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 SWOT Analysis
13.3.6 Johnson & Johnson
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Merck & Co. Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Pfizer Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings